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Abstract: MicroRNA (miRNA) are a class of non-coding, 19–25 nucleotide RNA critical 
for network-level regulation of gene expression. miRNA serve as paracrine signaling 
molecules. Using an unbiased array approach, we previously identified elevated levels of 
miR-224 and miR-103 to be associated with a monogenic form of diabetes; HNF1A-MODY. 
miR-224 is a novel miRNA in the field of diabetes. We sought to explore the role of miR-224 
as a potential biomarker in diabetes, and whether such diabetes-associated-miRNA can also 
be detected in the urine of patients. Absolute levels of miR-224 and miR-103 were determined 
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in the urine of n = 144 individuals including carriers of a HNF1A mutation, participants with 
type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and normal controls. 
Expression levels were correlated with clinical and biochemical parameters. miR-224 was 
significantly elevated in the urine of carriers of a HNF1A mutation and participants with 
T1DM. miR-103 was highly expressed in urine across all diabetes cohorts when compared 
to controls. For both miR-224 and-103, we found a significant correlation between serum 
and urine levels (p < 0.01). We demonstrate that miRNA can be readily detected in the urine 
independent of clinical indices of renal dysfunction. We surmise that the differential 
expression levels of miR-224 in both HNF1A-MODY mutation carriers and T1DM may be 
an attempt to compensate for beta-cell demise. 
Keywords: diabetes associated microRNA; miR-103; miR-224; urinary biomarker;  
insulin secretion 
 
1. Introduction 
miRNA have emerged as potent regulators of glucose homeostasis. miRNA are 19–25 nucleotide  
non-coding RNA molecules which suppress gene expression via imperfect base pairing to the 3' 
untranslated region of target mRNAs, leading to repression of protein production or mRNA degradation. 
miRNA have been shown to play a crucial role in pancreatic development [1,2], insulin secretion [2–4] 
and insulin resistance [5]. In addition to being potential therapeutic targets, miRNA are also considered 
as future diagnostics and biomarkers for disease progression and therapeutic responses. They are 
differentially expressed in tissues affected by diabetes when compared to normal controls, and have been 
detected in serum, plasma and whole blood in animal models and human subjects with diabetes [6–8]. 
Unique miRNA profiles have been identified in the serum of participants with diabetes, including both 
paediatric and adult cohorts [9–15]. miRNA have also been identified as biomarkers for micro- and 
macrovascular complications with the potential to be of clinical utility in diabetes care [16–19]. The role 
of circulating miRNA in diabetes has been studied almost exclusively using the serum of human subjects. 
However, microRNA detection in various more accessible body fluids has attracted recent attention [20]. 
HNF1A-maturity-onset diabetes of the young (HNF1A-MODY) is the most common monogenic 
form of diabetes resulting from mutations in the gene encoding the pancreatic transcription factor hepatocyte 
nuclear factor 1α (HNF1A) [21]. We recently demonstrated that induced suppression of endogenous 
HNF1A function in INS-1 cells, a cellular model of HNF1A-MODY [22–24], increased the levels of two 
specific miRNA; miR-224 and miR-103 [25]. Using absolute quantitative PCR analysis, we demonstrated 
that miR-224 and miR-103 levels were significantly elevated in the serum of HNF1A-MODY mutation 
carriers when compared to controls [25]. miR-103 has been previously shown to play a key role in insulin 
resistance and glucose homeostasis. The overexpression of miR-103 had been shown to result in 
impaired insulin sensitivity [5]. 
miRNA can be secreted from cells and accumulate in microvesicles, either bound to Ago2 protein, or 
as free miRNA in extracellular fluids [26–28]. Of note, HNF1A is expressed not only in the pancreas 
but also the liver, digestive tract and in particular the kidney [29]. Urine has proven to be a stable  
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biofluid [30] which can be acquired non-invasively and is not subject to collection difficulties such as 
the haemolysis associated with blood draw. The aim of this current study was to obtain proof-of-concept 
that miR-224 and miR-103 are detectable in the urine of HNF1A-MODY mutation carriers, and to 
determine whether these diabetes-associated miRNA are also elevated in the urine of patients with 
T1DM and T2DM. We also sought to correlate urinary levels of miRNA with serum levels, and with 
clinically relevant indices of renal disease. 
2. Experimental Section 
2.1. Patient Cohorts 
Individuals with a clinical diagnosis of MODY were recruited from the MODY diabetes clinic in the 
Mater Misericordiae University Hospital Dublin in Ireland. MODY is a monogenic, autosomal dominant 
form of diabetes. In contrast to type 1 diabetes mellitus (T1DM), patients with MODY are usually  
auto-antibody negative [islet cell antibody (ICA)/anti-glutamic acid decarboxylase (GAD)], non-ketotic 
and have detectable C-peptide suggesting preserved beta-cell function. Typically, at least one family 
member in a MODY pedigree is diagnosed under the age of 25 years. In the current study, genetically 
confirmed MODY carriers included 38 cases with HNF1A mutations. The mutations included G207D, 
P291finsC, S352fsdelG, F426X, P379T, E230fsdelGA, p.L502fs, p.Leu17His, p.R159Q, R200Q, 
S335X and V351fsdelG. Sequencing of the HNF1A gene was performed by IntegraGen (Bonn, Germany) 
in 2006–2007 and the Molecular Genetics Laboratory (Exeter, UK) in 2008–2014. Analysis of the 
HNF1A gene was performed by polymerase chain reaction (PCR) amplification of highly purified 
genomic DNA, followed by semi-automated unidirectional DNA sequencing of all exons, including the 
highly conserved flanking intronic sequences of the exon-intron splice junctions (HNF1A mRNA 
accession number NM_000545.5).The mutations named above have been previously published and  
co-segregate in families with diabetes [31,32]. The cohort with T1DM was selected based on the 
permanent usage of insulin since diagnosis, evidence of beta-cell dysfunction such as undetectable  
C-peptide and positive antibody status (GAD ± ICA). The cohort with T2DM was recruited based on 
not meeting the clinical criteria for a MODY diagnosis, specifically the absence of a significant family 
history, an older age at diagnosis and not being of lean body habitus. The normal control group was 
selected based on the detection of normoglycaemia, normotension and an absence of co-morbidities. 
Individuals were excluded from the control group if taking prescribed medication for hypertension or 
hyperlipidaemia. The study was approved by the Research Ethics Committee at the Mater Misericordiae 
University Hospital Dublin and all participants gave informed written consent. 
2.2. Phenotyping of the Cohort 
All participants underwent a clinical assessment including a full medical history and physical 
examination. We recorded details of any prescribed medication, in particular, antihypertensive agents, 
anticoagulants and lipid lowering medication. A urinary sample was collected in a fasting state and 
collected in a specimen jar (20 mL volume). A mid-stream clean catch void was advised. Immediately 
after collection, a 1 mL aliquot of urine was drawn from the specimen and immediately frozen. For miRNA 
analysis, 100 µL of the urine specimen was utilized. The remaining proportion was analyzed for 
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leukocytes and the albumin/creatinine ratio (ACR). The Urinary Albumin Creatinine Ratio (UACR)  
was calculated as the ratio between urinary albumin and creatinine. The UACR is not affected by urine 
concentration. Micro-albuminuria is said to be present when the UACR is 3.4–33.9 g/mol and overt 
albuminuria is present when the UACR is >34 g/mol. The CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration, http://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfr) creatinine equation was 
used for glomerular filtration rate (GFR) estimation. CKD was defined as an eGFR <60 mL/min/1.73 m2. 
Urinary osmolality was also measured using the Semi-micro Osmometer K-7400 (Knauer, Berlin, Germany). 
2.3. Oral Glucose Tolerance Test (OGTT) 
A 75 g OGTT was performed on participants with HNF1A-MODY and T2DM after an overnight fast 
with measurement of glucose, insulin and C-peptide at baseline and 30 min intervals to determine degree 
of glucose intolerance and insulin secretory response. The oral glucose insulin sensitivity (OGIS) was 
calculated as previously described using a calculation involving the weight, height, glucose and insulin 
levels at timed intervals during an OGTT [33]. 
2.4. Biochemical Assays 
All laboratory analyses were performed with commercially available standardized methods. The 
plasma glucose concentration was measured using Beckman Synchron DXC800 (Beckman Instruments Inc., 
Brea, CA, USA). HbA1c was determined using high performance liquid chromatography (Menarini 
HA81-10, Rome, Italy). Insulin and C-peptide were analyzed using Immulite 2000 immunoassay (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). Anti-GAD65 antibodies were analysed by ELISA (Euroimmun, 
Luebeck, Germany). ICA was performed by indirect immunofluorescence test by the supra-Regional 
Protein Reference Unit and Dept. of Immunology in Sheffield, UK. 
2.5. RNA Isolation from Human Urine 
Following centrifugation at 3000× g for 10 min at 4 °C, total RNA containing small RNA was 
extracted from 100 µL urine using the miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany).  
In brief, 700 µL of QIAzol reagent was added to 100 µL of urine sample and mixed well. To allow for 
normalization of sample-to-sample variation in RNA isolation, 25 fmol synthetic Caenorhabditis elegans 
miRNA cel-miR-39, (Sigma-Aldrich, Wickloe, Ireland) was added to each sample after 5 min incubation 
in QIAzol. Samples were mixed followed by adding 100 µL of chloroform. After mixing vigorously for 
15 s, samples were centrifugated at 12,000× g for 15 min at 4 °C. The upper aqueous phase was carefully 
transferred avoiding the interphase to a new tube, and 700 µL of ethanol was added and mixed. At that 
point, the manufacturer’s protocol was followed, with the entire aqueous phase from each sample loaded 
onto a single affinity column. Total RNA was eluted by adding 16 µL of RNase-free water to the 
membrane of the spin column and incubating for 1 min before centrifugation at 15,000× g for 1 min at 
room temperature and was stored at −80 °C. For the direct comparison of urine and serum miRNA levels, 
200 µL urine or serum were isolated and quantified as described in Bonner et al. [25]. The Ct values for 
the qPCR are contained in Supplementary Table S1. 
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Table 1. Clinical characteristics of patient groups. n.a. = not applicable, n.s. = not statistically significant, (*) = statistically significant with 
Bonferroni Correction. 
Parameter Normal Controls T1DM T2DM HNF1A-MODY Statistical Analysis p Value (Bonferroni Corrected) 
Group 0 1 2 3 0 vs. 1 0 vs. 2 0 vs. 3 1 vs. 2 1 vs. 3 2 vs. 3 
N 26 44 36 38       
Duration of diabetes (years) na 19 (4–28) 3 (1–8) 8 (2–24.25) n.a. n.a. n.a. 0.0009 (*) n.s. n.s. 
HbA1c (mmol/mol)/ (%) 
32.5 (31–35)/ 
9.2 (9.1–9.4) 
63 (55–75)/ 
8 (7.2–9) 
53 (49–65)/ 
7 (6.6–8.1) 
54 (44–63)/ 
7.1 (6.2–7.9) 
<0.0001 (*) <0.0001 (*) <0.0001 (*) 0.0044 (n.s.) 0.0014 (n.s.) n.s. 
SBP (mmHg) 121 (113–128) 125 (119.5–130) 135 (130–149.5) 120.5 (113.5–129) n.s. <0.0001 (*) n.s. 0.0003 (*) n.s. 0.0001 (*) 
DBP (mmHg) 73 (69–79) 76.5 (69–80) 80 (74–85) 71 (66.5–77) n.s. 0.0156 (n.s.) n.s. 0.0441 (n.s.) n.s. 0.0002 (*) 
T. Cholesterol (mmol/L) 4.8 (4.13–5.5) 4.25 (3.8–4.7) 4 (3.4–4.68) 4.35 (3.7–5.1) 0.0465 (n.s.) 0.0079 (n.s.) n.s. n.s. n.s. n.s. 
Creatinine (mmol/L) 79 (71.25–95) 70 (65.5–83) 76 (70–85.75) 68 (58–76.25) 0.0282 (n.s.) n.s. 0.0014 (n.s.) n.s. n.s. 0.0136 (n.s.) 
ACR (g/mol) 0 (0–0.8) 0.5 (0–1.33) 0.9 (0.5–2.7) 0.6 (0.4–0.96) n.s. 0.0001 (*) 0.0130 (n.s.) 0.0101 (n.s.) n.s. 0.0403 (n.s.) 
GFR (mL/min/1.73 m2) 74 (70–83) 89 (78–113) 85.5 (68–103) 88.5 (75–112) 0.0005 (*) n.s. 0.0024 (n.s.) n.s. n.s. n.s. 
Fasting C-Peptide (pmol/L) 367 (236.5–581) <66 924 (775–1295) 533 (365–681) n.a. 0.0009 (*) n.s. <0.0001 (*) n.a. 0.0001 (*) 
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2.6. Reverse Transcription and Quantitative Real-Time-PCR of Mature miRNA 
Reverse transcription (RT) reactions are performed using the TaqMan miRNA Reverse Transcription 
Kit (Life Technologies, Carlsbad, CA, USA) and mature miRNA-specific stem-loop primers [hsa-miR-224, 
AssayID_002099 (MI0000301), hsa-miR-103, AssayID_000439 (MI0000109)] according to the 
manufacturer’s instructions. Because the concentration of total RNA in urine has been below the limit 
of accurate quantitation by spectrophotometry, a fixed volume of 3 µL total RNA was used for cDNA 
preparation, as previously described [34]. For generation of standard curves, synthetic single-stranded 
RNA oligonucleotides corresponding to the mature miRNA sequences were purchased from Sigma-Aldrich. 
A serial of 10-fold dilutions of each oligonucleotide were made in water and run in parallel with the 
urine samples. 
Quantitative real-time PCR (qPCR) was performed in 96-well plates by use of the AIB 7500 
instrument (Applied Biosystems, Foster City, CA, USA). The qPCR reaction mixture (20 µL reaction 
volume) includes 1.33 µL product from RT reaction, 1 µL TaqMan MicroRNA Assay (Life Technologies, 
Carlsbad, CA, USA), 10 µL of TaqMan 2× Universal PCR Master Mix (no AmpErase) (Life Technologies, 
Carlsbad, CA, USA) and 7.67 µL nuclease-free water. Amplification was performed under following 
conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The cycle 
threshold (Ct) values were calculated with the SDS 2.1 software (Applied Biosystems, Foster City, CA, 
USA), with the automatic setting for automatic assigning of baseline and threshold for Ct determination. 
Each patient sample, sample with spike-in cel-miR-39 and dilutions of synthetic miRNA for generation 
of standard curve were run in triplicates. Ct measurements with high standard deviation between triplicates 
were considered outliers and excluded from further analysis. 
2.7. Absolute Quantification of miRNA and Data Normalization against Spiked-in Synthetic C. elegans 
miRNA Control 
Standard curves for each miRNA of interest were generated by plotting Ct values of the dilutions of 
synthetic miRNA vs. number of copies per reaction followed by exponential fitting. For normalisation of 
thus quantified miR-103 and miR-224 levels, a median normalization procedure with spike-in cel-miR-39 
was performed as previously described [34]. In brief, a normalisation factor for each sample was defined 
as ΔCt of mean cel-miR-39 run in triplicate to the median of all cel-miR-39 that were run in parallel. 
Quantifications of miRNA in patient samples were then normalised by dividing by 2ΔCt. 
2.8. Statistical Analysis 
Statistical analyses were performed using MatLab and its statistical toolbox (The MathWorks, Inc., 
Natick, MA, USA). The individual miRNA copy number was calculated based on 1.7 µL of urine. Areas 
under the curves (AUCs) for insulin, glucose and C-peptide were calculated using the trapezoidal rule. 
Data are given as median and interquartile range (IQR) and were compared by Mann-Whitney U test 
and Spearman correlation analysis. Repeated samples of urine were analyzed using Wilcoxon signed 
rank test for paired data. Categorical data such as medication usage was compared using Fisher’s exact 
test. The potential of miRNA to discriminate between normal controls and participants of the T1DM, 
T2DM or HNF1A-MODY mutation carrier groups or a pooled group thereof were assessed by receiver 
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operating characteristic (ROC) analysis. In the ROC analysis, each level of miRNA is tested as a 
potential cut-off to distinguish between two groups. The resulting sensitivity and specificity is presented 
as a curve where an AUC = 1 would indicate perfect discrimination. An association between miRNA 
and renal indices was investigated by linear regression analysis and Spearman correlation. Hypotheses 
tests were considered statistically significant if p < 0.05. 
3. Results and Discussion 
3.1. Clinical Characteristics of All Groups 
A total of 144 individuals participated in the study. The clinical characteristics of the HNF1A-MODY 
mutation carriers (n = 38), T1DM (n = 44), T2DM (n = 36) and controls (n = 26) are contained in Table 1. 
The HNF1A-MODY carriers, T1DM and control groups were matched for age [41.5 years (21–52),  
37 years (23–49.5) and 38 years (30–44), respectively, p = n.s.] and BMI [24.1 kg/m2 (21.8–25),  
25 kg/m2 (22–27) and 23.4 kg/m2 (22–27), respectively, p = n.s.]. 
In terms of metabolic parameters, the HNF1A-MODY carriers, T1DM and control groups were 
comparable for systolic blood pressure (SBP), diastolic blood pressure (DBP), high density lipoprotein 
(HDL) cholesterol, total cholesterol, low density lipoprotein (LDL) cholesterol and triglyceride level. 
As expected, the T2DM group had a higher DBP [median [IQR] 80 mmHg (73–85)) and triglyceride 
level (1.24 mmol/L (0.8–2.68)] than all the remaining groups (p < 0.05). There was a significantly lower 
use of secondary preventative medication amongst both the HNF1A-MODYmutation carriers and 
T1DM group when compared to the T2DM group. Specifically, in the HNF1A-MODY mutation carriers 
there was lower use of aspirin (31.5% vs. 69.4%, p ≤ 0.05), anti-hypertensive agents (15.7% vs.58.3%  
p ≤ 0.05) and lipid lowering medications in particular statin therapy (69.4% vs. 23.6%, p ≤ 0.05) when 
compared to the T2DM group. Likewise, in the T1DM group there was a lower use of aspirin (36.3% vs. 
69.4%, p ≤ 0.05) and anti-hypertensive agents (34% vs. 58.3% p ≤ 0.05) when compared to the T2DM group. 
As expected, the T1DM group had the highest HbA1c when compared to all remaining groups  
[63 mmol/mol (8%) (55–75) / (7.2–9); p < 0.05] with an undetectable C-peptide level (<66 mmol/L).  
The T2DM group had a lower OGIS level than the HNF1A-MODY mutation carriers [295 mL/min/m2 
(223–344) vs. 355 mL/min/m2 (296–410) p < 0.05] in keeping with the presence of insulin resistance. 
3.2. miR-224 is Detectable in Urine and is Highly Expressed in HNF1A-MODY Mutation Carriers and 
Participants with T1DM 
In our initial report, we identified a strong association between elevated serum levels of miR-224 and 
the presence of a HNF1A-MODY mutation [25]. To test whether miR-224 was also detectable in the 
urine of participants with diabetes, RNA from human urine samples was isolated and hsa-miR-224 
expression was quantitated via TaqMan qPCR assays. Samples were measured in triplicate using 
synthetic miR-224 single-stranded RNA Oligonucleotides as standards to obtain absolute miRNA copy 
numbers that were furthermore normalized against spiked-in synthetic C. elegans miRNA control. miR-224 
levels were detected at a significantly higher level in the urine of HNF1A-MODY mutation carriers 
when compared to the control group [2790 × 103 copies per 1.7 µL (1430–7990 × 103) vs. 1180 × 103 
copies per 1.7 µL (575–2030 × 103), p < 0.05] (Figure 1). In a subgroup of patients, a repeat urine sample 
Genes 2015, 6 406 
 
 
was attained during clinical follow up (median follow up; 16 months [4–36 months]) and analyzed to 
determine repeat levels of miR-224. On repeat analysis, there was no significant difference in expression 
levels for miR-224 [(initial sample) 660 × 103 copies per 1.7 µL vs. (subsequent sample) 710 × 103 
copies per 1.7 µL, p = 0.5], again emphasizing the robust nature of miR-224. In addition, we compared 
HNF1A-MODY mutation carriers with the highest levels of miR-224 to those having a “low to normal” 
level for all clinical parameters including age, duration, BMI and HbA1c. Findings demonstrate that 
participants with the highest miR-224 values have measurements within the same range as the “low to 
normal” group for the clinical parameters studied. 
We also determined urine levels of miR-224 in individuals with T1DM and T2DM (Figure 1). miR-224 
was significantly elevated in the urine of individuals with T1DM when compared to controls [2380 × 103 
copies per 1.7 µL (1120–7970 × 103) vs. 1180 × 103 copies per 1.7 µL (575–2030 × 103), p < 0.05], but 
there was no significant difference noted in miR-224 levels in the T1DM population studied when 
compared to the HNF1A-MODY group [2380 × 103 copies per 1.7 µL (1120–7970 × 103) vs. 2790 × 103 
copies per 1.7 µL (1430–7990 × 103), p = 0.8]. miR-224 expression levels were significantly higher in 
both the HNF1A-MODY mutation carriers and T1DM groups when compared to the T2DM group 
[HNF1A-MODY mutation carriers: 2790 × 103 copies per 1.7 µL (1430–7990 × 103) vs. 1520 × 103 
copies per 1.7 µL (630–3960 × 103), p < 0.05] and [T1DM: 2380 × 103 copies per 1.7 µL (1120–7970 × 103) 
vs. 1520 × 103 copies per 1.7 µL (630–3960 × 103), p < 0.05]. 
The ROC analysis for miR-224 in theHNF1A-MODY mutation carriers, T1DM, T2DM and normal 
control groups are presented in Figure 2. miR-224 can reasonably differentiate HNF1A-MODY from 
normal controls (AUC = 0.74) as well as T1DM from normal controls (AUC = 0.76). Furthermore, ROC 
analysis of pooled groups with diabetes (T1DM, T2DM and HNF1A-MODY mutation carriers) indicates 
that miR-224 can distinguish between normal controls and diseased patients (AUC = 0.72). 
3.3. miR-103 is Detectable in Urine and is Highly Expressed in Patients with Diabetes 
We also found strongly elevated levels of miR-103 in the urine of HNF1A-MODY mutation carriers 
when compared to the control group [median [IQR] 2020 × 103 copies per 1.7 µL (622–5840 × 103) vs. 
559 × 103 copies per 1.7 µL (385–997 × 103) p < 0.05] (Figure 3). Similar to miR-224, we found no 
significant difference on subsequent measurement for miR-103 [(initial sample) 390 × 103 copies per 
1.7 µL vs. (subsequent sample) 260 × 103 copies per 1.7 µL, p = 0.6]. 
We next determined urine levels of miR-103 in individuals with T1DM and T2DM. There were 
significantly higher levels of miR-103 in the urine of individuals with T1DM and T2DM when compared 
to controls [T1DM: 1800 × 103 copies per 1.7 µL (698–453 × 103) vs. 559 × 103 copies per 1.7 µL  
(385–997 × 103), p < 0.05) and [T2DM: 1300 × 103 copies per 1.7 µL (478–309 × 103) vs. 559 copies 
per 1.7 µL (385–997 × 103), p < 0.05], respectively. There was no difference noted in miR-103 
expression levels between all diabetes cohorts studied (T1DM, T2DM and HNF1A-MODY mutation 
carriers) (Figure 3). 
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Figure 1. miR-224 levels detected in urine. Copies of miRNA per reaction were determined 
by quantitative qPCR in urine samples of T1DM (n = 44), T2DM (n = 36), HNF1A-MODY 
(n = 38) and normal control (n = 26) subjects. Box plots depict median and inter quartile range. 
The HNF1A-MODY mutation carriers had the highest median value of miR-224 and was 
significantly different from normal controls showing the lowest median value. In addition, the 
T1DM group had a higher median value than normal controls. miR-224 expression levels in the 
T2DM group were significantly lower than in T1DM group and the HNF1A-MODY mutation 
carriers but were similar to normal controls. (* significant differences by Mann-Whitney test). 
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Figure 2. ROC analysis of miR-224. Levels of miR-224 in urine differentiated the normal 
control group from the T1DM, HNF1A-MODY mutation carrier and T2DM groups, respectively. 
 
Figure 3. miR-103 levels detected in urine. Copies of miRNA per reaction were determined 
by quantitative qPCR in urine samples of T1DM (n = 44), T2DM (n = 36), HNF1A-MODY 
mutation carriers (n = 38) and normal control (n = 26) subjects. Box plots depict median and 
inter quartile range. Levels of miR-103 were statistically higher in all disease groups compared 
to normal controls where HNF1A-MODY mutation carriers showed the highest expression 
values (* significant differences by Mann-Whitney test). 
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3.4. Correlation of Urine miR-224 and miR-103 Levels with Clinical and Biochemical Characteristics 
We next performed Spearman correlation analyses to identify any correlation of urine miRNA levels 
with clinical and biochemical parameters (Supplementary Table S2). Since any published work available 
to date on urinary miRNA has been performed in the setting of renal pathology, we analyzed any potential 
correlation of miR-224 and miR-103 levels with indices of renal disease. The median eGFR was  
>60 mL/min/1.73 m2 in all groups signifying the absence of overt renal disease. Likewise, the median ACR 
values in all patients studied did not reveal microalbuminuria or overt albuminuria. The miR-224 and 
miR-103 levels in HNF1A-MODY mutation carriers, T1DM or T2DM did not correlate with the renal 
indices; ACR or eGFR (Figure 4). In addition, there was no correlation detected between miR-224 and 
miR-103 and urinary osmolality (miR-224; ρ = 0.04, p = 0.6 and miR-103; ρ = −0.002, p = 0.9). Serum and 
urine miRNA analysis performed in matched cohort samples, using identical miRNA quantification methods 
revealed a significant correlation between serum and urine miRNA levels (miR-224: ρ = 0.55, p ≤ 0.01 
and miR-103: ρ = 0.38, p = 0.01). Figure 5 demonstrates the statistically significant association between 
serum and urine for miR-224 in a cohort of HNF1A-MODY mutation carriers and normal controls. 
 
Figure 4. Correlation of miR-224 and miR-103 with renal indices; eGFR/ACR. Linear 
regression analysis indicates no statistically significant association of miR-224/-103 with 
GFR/ACR in the HNF1A-MODY mutation carrier, T1DM, T2DM and normal control 
groups; n.s. not significant. 
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Figure 5. Correlation of miR-224 in the serum and urine of a matched cohort of HNF1A-MODY 
mutation carriers (n = 30) and normal controls (n = 8). Spearman correlation analyses 
demonstrated a significant correlation between serum and urine for miR-224 (R2 = 0.5,  
p < 0.003). 
4. Discussion 
miRNA represent an important mechanism in the regulation of gene expression and the potential to 
manipulate this expression has significant implications in the management of disease states including 
diabetes. In this study, we report, for the first time, detection of circulating diabetes-associated miR-224 
and miR-103 in the urine of patients, notably in the absence of renal pathology. This is also the first 
study to detect miRNA in the urine of a large cohort of HNF1A-MODY mutation carriers. HNF1A-MODY 
is a monogenic form of diabetes and therefore an ideal model for the study of the beta-cell. HNF1A-MODY 
is primarily a disorder resulting in beta-cell dysfunction, with mutation carriers lacking features of the 
metabolic syndrome such as insulin resistance, as opposed to the multifactorial aetiology synonymous 
with T2DM. We chose to study miR-224 and miR-103 in particular based on preliminary work performed 
in our laboratory whereby the endogenous expression of HNF1A in INS-1 cell lines resulted in the 
elevated expression of both miR-224 and miR-103 [25]. 
Of interest, we have found that miR-224 is highly expressed in the urine of patients with T1DM and 
HNF1A-MODY mutation carriers when compared to both the T2DM and the normal control cohorts. 
miR-224 is a novel miRNA in the field of diabetes. To date, it has been shown that miR-224 is aberrantly 
expressed in a wide variety of malignancies including prostatic, hepatocellular, renal cell and colorectal. 
It is known to promote cell migration, proliferation, and invasion and has been shown to target TGF-β 
signaling via the Smad 4 pathway [35–38]. The elevated expression of miR-224 in both HNF1A-MODY 
mutation carriers and T1DM is not surprising given that both share certain traits. Beta-cell failure and 
ultimately a reduction in beta-cell mass are noted in both HNF1A-MODY mutation carriers and  
T1DM [39,40]. In contrast to T2DM, which is a relative insulin deficient state with the pathology 
attributed largely to insulin resistance, it is a defect in insulin secretion that is the principal pathology of 
both HNF1A-MODY mutation carriers and T1DM [41]. This defect predates the clinical manifestation 
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of diabetes as demonstrated by research in the carriers of HNF1A-MODY who were normoglycaemic 
and likewise in islet antibody positive relatives of those with T1DM [42,43]. We can hypothesize that 
the altered miR-224 expression profile may be a contributor to the beta-cell dysfunction noted in both 
HNF1A-MODY mutation carriers and T1DM. We can speculate that miR-224, as a marker of beta-cell 
demise, has the potential to be an important clinical development given the current inability to perform 
pancreatic biopsies in humans and lack of beta-cell imaging techniques. There are currently no available 
biomarkers of beta-cell demise. 
miR-224 was significantly elevated in the urine of HNF1A-MODY mutation carriers when compared 
to the T2DM cohort studied. We therefore propose that the clinical utility of miR-224 may be further 
expanded as an additional screening tool to decipher who should be screened for HNF1A-MODY genetic 
testing. This is of clinical relevance, given that it is not feasible to perform genetic testing on all potential 
mutation carriers, and the greatest clinical challenge is in the discrimination of potential HNF1A-MODY 
mutation carriers from lean patients with T2DM. 
In the current study, miR-103 was highly expressed in the urine of all participants with diabetes when 
compared to the normal control cohort. To our knowledge, this is the first description of miR-103 in the 
urine of patients with diabetes. A recently published meta-analysis ranked miR-103 as one of the most 
common, consistently deregulated miRNA in diabetes across multiple tissue types including pancreatic, 
adipose and serum [44]. Our novel finding of such a well-established diabetes-associated marker in urine 
of patients with both mono- and polygenic forms of diabetes lends credence to the validity of the 
methodology employed to detect miRNA in the current study. Whilst the pathway regulated by miR-224 is 
not fully elucidated, the principal targets of miR-103 have been investigated extensively. Caveolin 1 is 
a known target of miR-103; in vitro studies have previously demonstrated that caveolin 1 interacts with 
the insulin receptor improving insulin mediated phosphorylation of IRS-1 [5]. Cav-1 deficient mice 
develop post-prandial hyperglycaemia and insulin resistance. It may be that the increased miR-103 
expression in diabetes is an attempt to surmount the lack of insulin with enhanced insulin signaling. 
In the current study, we can only speculate as to the origin of miR-224 and miR-103 in the urine of 
individuals with diabetes. The miRNA detected in the urine may have originated from beta-cells or 
indeed from tissues affected by diabetes such as liver, muscle, or kidneys. It is also possible that miRNA 
are actively secreted by the kidneys. A likely explanation is that miRNA derive in urine (at lower 
quantities than in serum) from the blood through the process of glomerular filtration. The approximate 
molecular weight of miRNA is 6.2–7.2 kDa [45]. The threshold of the glomerular filtration barrier is 
approximately 60 kDa. Therefore, a substantial portion of circulating miR-224 and miR-103 could be 
ultra-filtrated through the kidneys. 
The utilization of urine as a biofluid has multiple advantages in the clinical setting. Urine sampling is 
non-invasive and it is collected at every diabetes and nephrology clinic. Urine is not subject to haemolysis. 
This of utmost importance, as blood contamination and haemolysis are the two most common artefacts 
encountered in miRNA detection in fluids acquired by invasive means (serum/plasma/CSF) [20,45,46]. 
A publication by Mall et al. showed that urinary miRNA remain stable under harsh conditions including 
freeze/thaw cycles and prolonged storage at room temperature. Although there may be some degradation 
over time, lower levels have been shown to remain detectable [30]. We have performed repeat urinary 
miR-224 and miR-103 measurements on a subset of participants. The repeat samples were drawn on 
separate days in a non-fasting state. There was no significant difference noted between both measurements. 
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These particular urinary miRNA appear to be robust and independent of dietary restriction which is 
important in a clinical setting. 
A limitation of the current investigation is that we cannot provide a definitive causation for the 
differential expression of urinary miR-224 between the different forms of diabetes. However, reassuringly, 
we have demonstrated that the elevated expression of miR-224 and miR-103 levels is a common 
phenotype in vitro, in serum and now in the urine of HNF1A-MODY mutation carriers. As aforementioned, 
HNF1A-MODY represents an ideal beta-cell model. The establishment of gene manipulated in vitro and 
rodent models may facilitate the functional analyses of such miRNA and promote further translational 
research for the diagnosis and treatment of diabetes. A further strength of this study is the inclusion of 
both mono- and polygenic diabetes forms. 
5. Conclusions 
In conclusion, we here provide the first proof-of-concept study that miRNA can be readily detected 
in the urine of participants with diabetes. miR-224 is a novel diabetes-associated miRNA which is highly 
expressed in the urine of HNF1A-MODY mutation carriers and a T1DM cohort. We surmise that the 
differential expression levels of miR-224 in both insulin deficient states may be an attempt to compensate 
for beta-cell demise. A further novel finding of the current study is the detection of the well-established 
diabetes-associated miR-103 in urine. Finally, our study highlights the benefits in the use of urine as a 
biofluid for miRNA detection in the clinical setting. 
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